TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06016335

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Participants receive an MRI scan, specifically for the purpose of the study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Participants receive an MRI scan, specifically for the purpose of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Synthetic CT scan
Description: Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
Study: NCT05399602

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: External lumbar drainage
Description: External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar infusion test
Description: Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
Study: NCT04264026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
Study: NCT06499857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3ml pen-injector containing placebo solution for subcutaneous use.
Study: NCT05523154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of bile samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bile samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Procedure
Description: Undergo routine laboratory testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Procedure
Description: Undergo routine laboratory testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanopore Sequencing
Description: Undergo nanopore sequencing
Study: NCT04914221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2002
Description: administration of JLP-2002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2002
Description: administration of JLP-2002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2002
Description: administration of JLP-2002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator
Description: administration of comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator
Description: administration of comparator
Study: NCT06367023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rajyoga Meditation Practice
Description: The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
Study: NCT04914221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator
Description: administration of comparator
Study: NCT05603377

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: functional endoscopic evaluation of swallow
Description: functional endoscopic evaluation of swallow
Study: NCT06244849

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stool simple
Description: A fresh stool sample will be collected and conserved at room temperature until shipment

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stool simple
Description: A fresh stool sample will be collected and conserved at room temperature until shipment

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ileocolonic biopsies
Description: An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ileocolonic biopsies
Description: An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
Study: NCT06160700

Intervention type: BEHAVIORAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
Study: NCT05399602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventriculo-peritoneal shunt placement
Description: Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prechamber puncture
Description: Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #1
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling #1
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P1012815, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P1012815, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P1012815, a nicotine pouch with 8 mg nicotine
Study: NCT05788614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Description: Reverse shoulder arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Description: Reverse shoulder arthroplasty
Study: NCT05423795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine-based intervention
Description: Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care arm
Description: Classic expertise (as routinely performed in the participating ICU)
Study: NCT04842838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel DCB
Description: Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES
Description: Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
Study: NCT05645159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended learning in heart disease
Description: The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine
Study: NCT04689867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
Description: Cognitive and behavioral approach to suicide prevention among individuals with psychosis
Study: NCT04719260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Thinking®
Description: In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutritional Approach
Description: In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
Study: NCT04632511

Intervention type: DEVICE
Group type: OTHER
Intervention: MetaSAMP
Description: Rectal Sampler

Intervention type: DEVICE
Group type: OTHER
Intervention: MetaSAMP
Description: Rectal Sampler
Study: NCT05420480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Field lymph node dissection
Description: The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-Field lymph node dissection
Description: The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Three-Field lymph node dissection
Description: The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed.
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: P1013215, a nicotine pouch with 8 mg nicotine
Study: NCT05503394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support WeChat platform intervention
Description: Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine nursing care group
Description: Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine nursing care group
Description: Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
Study: NCT06106178

Intervention type: OTHER
Group type: OTHER
Intervention: Simulator for Basic Ultrasound Skills
Description: Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
Study: NCT04710849

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic markers
Description: Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum metabolic markers
Description: Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
Study: NCT06322446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
Study: NCT05766540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 MG
Description: Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aripiprazole 10 MG
Description: Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
Study: NCT05326971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastroscopy
Description: Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
Study: NCT05399602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #2
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling #2
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #3
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling #3
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling #4 and #5
Description: Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
Study: NCT04632511

Intervention type: DEVICE
Group type: OTHER
Intervention: MetaSAMP
Description: Rectal Sampler
Study: NCT06041152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 2 macrodoses of 25mg separated by one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 2 macrodoses of 25mg separated by one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo separated by one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo separated by one week.
Study: NCT05448508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic lancet
Description: An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
Study: NCT05856630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate Sustained-Release Microspheres for Injection
Description: 10.8mg, Single dose, subcutaneously（SC）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex 10.8 MG Drug Implant
Description: 10.8mg, Single dose, subcutaneously（SC）
Study: NCT04730037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: - Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Potassium
Description: - Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Potassium placebo
Description: - Warfarin K 1 mg placebo tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban placebo
Description: - Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications